Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of venetoclax performance using its new derivatives on BCL‐2 protein inhibition

18 Oct 2022

Abstract excerpt

Cancer cells are resistant to apoptosis and this is one of the most obvious symptoms of cancer in humans. One of the most exciting strategies for treating cancer is to design regulators that increase cell death and stop cell growth. Members of the BCL-2 family of proteins play an important role in the regulation of apoptosis. In this study, an attempt was made to improve the performance of one of the anticancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Cell death mechanisms and regulation
Share to Metal complexes synthesis and properties

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36259104
DOI: 10.1002/cbf.3760

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of venetoclax performance using its new derivatives on BCL‐2 protein inhibitionPMID 36259104Read ↗

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor VenetoclaxSemantic proximity Read ↗

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity Read ↗

Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small moleculesSemantic proximity Read ↗

Mechanisms of venetoclax resistance and solutionsSemantic proximity Read ↗

Targeting Bcl-2 Proteins in Acute Myeloid LeukemiaSemantic proximity Read ↗

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsSemantic proximity Read ↗

Progress in understanding the mechanisms of resistance to BCL-2 inhibitorsSemantic proximity Read ↗

Targeting Bcl-2 Family Proteins: What, Where, When?Semantic proximity Read ↗

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell MalignanciesSemantic proximity Read ↗

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.Semantic proximity Read ↗

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity Read ↗

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.